These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

270 related items for PubMed ID: 9351459

  • 1. Potentiation of the actions of bradykinin by angiotensin I-converting enzyme inhibitors. The role of expressed human bradykinin B2 receptors and angiotensin I-converting enzyme in CHO cells.
    Minshall RD, Tan F, Nakamura F, Rabito SF, Becker RP, Marcic B, Erdös EG.
    Circ Res; 1997 Nov; 81(5):848-56. PubMed ID: 9351459
    [Abstract] [Full Text] [Related]

  • 2. Enhancement of bradykinin and resensitization of its B2 receptor.
    Marcic B, Deddish PA, Jackman HL, Erdös EG.
    Hypertension; 1999 Mar; 33(3):835-43. PubMed ID: 10082496
    [Abstract] [Full Text] [Related]

  • 3. Protein kinase C and phosphatase inhibitors block the ability of angiotensin I-converting enzyme inhibitors to resensitize the receptor to bradykinin without altering the primary effects of bradykinin.
    Marcic BM, Erdös EG.
    J Pharmacol Exp Ther; 2000 Aug; 294(2):605-12. PubMed ID: 10900238
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Studies on the angiotensin-converting enzyme and the kinin B2 receptor in the rabbit jugular vein: modulation of contractile response to bradykinin.
    Gobeil F, Hallé S, Blais PA, Regoli D.
    Can J Physiol Pharmacol; 2002 Feb; 80(2):153-63. PubMed ID: 11934258
    [Abstract] [Full Text] [Related]

  • 6. Replacement of the transmembrane anchor in angiotensin I-converting enzyme (ACE) with a glycosylphosphatidylinositol tail affects activation of the B2 bradykinin receptor by ACE inhibitors.
    Marcic B, Deddish PA, Skidgel RA, Erdös EG, Minshall RD, Tan F.
    J Biol Chem; 2000 May 26; 275(21):16110-8. PubMed ID: 10748135
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. N-domain-specific substrate and C-domain inhibitors of angiotensin-converting enzyme: angiotensin-(1-7) and keto-ACE.
    Deddish PA, Marcic B, Jackman HL, Wang HZ, Skidgel RA, Erdös EG.
    Hypertension; 1998 Apr 26; 31(4):912-7. PubMed ID: 9535414
    [Abstract] [Full Text] [Related]

  • 10. Hydrolysis of angiotensin peptides by human angiotensin I-converting enzyme and the resensitization of B2 kinin receptors.
    Chen Z, Tan F, Erdös EG, Deddish PA.
    Hypertension; 2005 Dec 26; 46(6):1368-73. PubMed ID: 16246972
    [Abstract] [Full Text] [Related]

  • 11. Kallikrein activates bradykinin B2 receptors in absence of kininogen.
    Biyashev D, Tan F, Chen Z, Zhang K, Deddish PA, Erdös EG, Hecquet C.
    Am J Physiol Heart Circ Physiol; 2006 Mar 26; 290(3):H1244-50. PubMed ID: 16272198
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Pharmacological characterization of the bradykinin B2 receptor: inter-species variability and dissociation between binding and functional responses.
    Paquet JL, Luccarini JM, Fouchet C, Defrêne E, Loillier B, Robert C, Bélichard P, Cremers B, Pruneau D.
    Br J Pharmacol; 1999 Mar 26; 126(5):1083-90. PubMed ID: 10204994
    [Abstract] [Full Text] [Related]

  • 14. Potentiation of the vascular response to kinins by inhibition of myocardial kininases.
    Dendorfer A, Wolfrum S, Schäfer U, Stewart JM, Inamura N, Dominiak P.
    Hypertension; 2000 Jan 26; 35(1 Pt 1):32-7. PubMed ID: 10642271
    [Abstract] [Full Text] [Related]

  • 15. Angiotensin-(1-7) augments bradykinin-induced vasodilation by competing with ACE and releasing nitric oxide.
    Li P, Chappell MC, Ferrario CM, Brosnihan KB.
    Hypertension; 1997 Jan 26; 29(1 Pt 2):394-400. PubMed ID: 9039133
    [Abstract] [Full Text] [Related]

  • 16. Potentiation of kinin analogues by ramiprilat is exclusively related to their degradation.
    Dendorfer A, Reibetamann S, Wolfrum S, Raasch W, Dominiak P.
    Hypertension; 2001 Jul 26; 38(1):142-6. PubMed ID: 11463775
    [Abstract] [Full Text] [Related]

  • 17. Bradykinin potentiation by angiotensin-(1-7) and ACE inhibitors correlates with ACE C- and N-domain blockade.
    Tom B, de Vries R, Saxena PR, Danser AH.
    Hypertension; 2001 Jul 26; 38(1):95-9. PubMed ID: 11463767
    [Abstract] [Full Text] [Related]

  • 18. Potentiation of bradykinin effect by angiotensin-converting enzyme inhibition does not correlate with angiotensin-converting enzyme activity in the rat mesenteric arteries.
    Sivieri DO, Bispo-da-Silva LB, Oliveira EB, Resende AC, Salgado MC.
    Hypertension; 2007 Jul 26; 50(1):110-5. PubMed ID: 17470724
    [Abstract] [Full Text] [Related]

  • 19. Depressor action of bradykinin agonists relative to metabolism by angiotensin-converting enzyme, carboxypeptidase N, and aminopeptidase P.
    Ahmad S, Ward PE.
    Proc Soc Exp Biol Med; 1992 May 26; 200(1):115-21. PubMed ID: 1315058
    [Abstract] [Full Text] [Related]

  • 20. Potentiation of the effects of bradykinin on its receptor in the isolated guinea pig ileum.
    Minshall RD, Nedumgottil SJ, Igić R, Erdös EG, Rabito SF.
    Peptides; 2000 Aug 26; 21(8):1257-64. PubMed ID: 11035213
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.